HAEM5:Monoclonal B-cell lymphocytosis - Revision history

Richard.Glen at 00:49, 26 February 2026

2026-02-26T00:49:37Z

← Older revision		Revision as of 19:49, 25 February 2026
Line 272:		Line 272:
	Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>		Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>
	==References==		==References==
	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span><references />		(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>
			<references />

	==Notes==		==Notes==

Richard.Glen at 00:37, 26 February 2026

2026-02-26T00:37:39Z

← Older revision		Revision as of 19:37, 25 February 2026
Line 272:		Line 272:
	Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>		Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>
	==References==		==References==
	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>		(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span><references />

	==Notes==		==Notes==

Bailey.Glen at 17:21, 3 July 2025

2025-07-03T17:21:25Z

← Older revision		Revision as of 12:21, 3 July 2025
Line 35:		Line 35:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:41, 25 May 2025

2025-05-25T21:41:42Z

← Older revision		Revision as of 16:41, 25 May 2025
Line 124:		Line 124:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 179:		Line 179:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 212:		Line 212:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:17, 25 May 2025

2025-05-25T20:17:13Z

← Older revision		Revision as of 15:17, 25 May 2025
Line 50:		Line 50:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

	==Gene Rearrangements==		==Gene Rearrangements==
	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>

Bailey.Glen at 17:40, 24 March 2025

2025-03-24T17:40:44Z

← Older revision		Revision as of 12:40, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Monoclonal B-cell lymphocytosis}}		{{DISPLAYTITLE:Monoclonal B-cell lymphocytosis}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Bailey.Glen at 22:01, 13 February 2025

2025-02-13T22:01:34Z

Show changes

Bailey.Glen: /* Gene Rearrangements */

2025-02-13T21:58:24Z

Gene Rearrangements

← Older revision		Revision as of 16:58, 13 February 2025
Line 62:		Line 62:

	==Gene Rearrangements==		==Gene Rearrangements==
			Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
			{\| class="wikitable sortable"
			\|-
			!Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s)
			!Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease)
			!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
			!Established Clinical Significance Per Guidelines - Yes or No (Source)
			!Clinical Relevance Details/Other Notes
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''ABL1''\|\|<span class="blue-text">EXAMPLE:</span> ''BCR::ABL1''\|\|<span class="blue-text">EXAMPLE:</span> The pathogenic derivative is the der(22) resulting in fusion of 5’ BCR and 3’ABL1.\|\|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)
			\|<span class="blue-text">EXAMPLE:</span> Common (CML)
			\|<span class="blue-text">EXAMPLE:</span> D, P, T
			\|<span class="blue-text">EXAMPLE:</span> Yes (WHO, NCCN)
			\|<span class="blue-text">EXAMPLE:</span>
			The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). BCR::ABL1 is generally favorable in CML (add reference).
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''CIC''
			\|<span class="blue-text">EXAMPLE:</span> ''CIC::DUX4''
			\|<span class="blue-text">EXAMPLE:</span> Typically, the last exon of ''CIC'' is fused to ''DUX4''. The fusion breakpoint in ''CIC'' is usually intra-exonic and removes an inhibitory sequence, upregulating ''PEA3'' genes downstream of ''CIC'' including ''ETV1'', ''ETV4'', and ''ETV5''.
			\|<span class="blue-text">EXAMPLE:</span> t(4;19)(q25;q13)
			\|<span class="blue-text">EXAMPLE:</span> Common (CIC-rearranged sarcoma)
			\|<span class="blue-text">EXAMPLE:</span> D
			\|
			\|<span class="blue-text">EXAMPLE:</span>

			''DUX4'' has many homologous genes; an alternate translocation in a minority of cases is t(10;19), but this is usually indistinguishable from t(4;19) by short-read sequencing (add references).
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''ALK''
			\|<span class="blue-text">EXAMPLE:</span> ''ELM4::ALK''


	~~Put your~~ text ~~here and fill~~ in the ~~table~~		Other fusion partners include ''KIF5B, NPM1, STRN, TFG, TPM3, CLTC, KLC1''
			\|<span class="blue-text">EXAMPLE:</span> Fusions result in constitutive activation of the ''ALK'' tyrosine kinase. The most common ''ALK'' fusion is ''EML4::ALK'', with breakpoints in intron 19 of ''ALK''. At the transcript level, a variable (5’) partner gene is fused to 3’ ''ALK'' at exon 20. Rarely, ''ALK'' fusions contain exon 19 due to breakpoints in intron 18.
			\|<span class="blue-text">EXAMPLE:</span> N/A
			\|<span class="blue-text">EXAMPLE:</span> Rare (Lung adenocarcinoma)
			\|<span class="blue-text">EXAMPLE:</span> T
			\|
			\|<span class="blue-text">EXAMPLE:</span>

	~~{\| class="wikitable sortable"~~		Both balanced and unbalanced forms are observed by FISH (add references).
	\|-		\|-
	~~!Chromosomal Rearrangement!!Genes~~ in ~~Fusion~~ (~~5’ or 3’ Segments~~)~~!!Pathogenic Derivative!!Prevalence~~		\|<span class="blue-text">EXAMPLE:</span> ''ABL1''
	~~!Diagnostic Significance (Yes~~, ~~No or Unknown)~~		\|<span class="blue-text">EXAMPLE:</span> N/A
	~~!Prognostic Significance (Yes~~, ~~No or Unknown)~~		\|<span class="blue-text">EXAMPLE:</span> Intragenic deletion of exons 2–7 in ''EGFR'' removes the ligand-binding domain, resulting in a constitutively active tyrosine kinase with downstream activation of multiple oncogenic pathways.
	~~!Therapeutic Significance (Yes, No or Unknown)~~		\|<span class="blue-text">EXAMPLE:</span> N/A
	~~!Notes~~		\|<span class="blue-text">EXAMPLE:</span> Recurrent (IDH-wildtype Glioblastoma)
			\|<span class="blue-text">EXAMPLE:</span> D, P, T
			\|
			\|
	\|-		\|-
	\|~~<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)~~\|\|~~<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR~~\|\|~~<span class="blue-text">EXAMPLE:</span> der(22)\|\|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)~~		\|
	~~<span class="blue-text">EXAMPLE:</span> 30% (add reference)~~		\|
	\|~~Yes~~		\|
	\|No		\|
	\|~~Yes~~		\|
	\|~~<span class="blue-text">EXAMPLE:</span>~~		\|
			\|
			\|
			\|}

	~~The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).~~
	\|}

	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==

Bailey.Glen: Removed old template contents

2025-02-13T02:21:58Z

Removed old template contents

@@ Line 1: / Line 1: @@
 {{DISPLAYTITLE:Monoclonal B-cell lymphocytosis}}
 [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
 {{Under Construction}}
-<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Monoclonal B-cell Lymphocytosis]].
+<blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Monoclonal B-cell Lymphocytosis]].
 }}</blockquote>
@@ Line 33: / Line 34: @@
 |Subtype(s)
 |Monoclonal B-cell lymphocytosis
 |}
@@ Line 303: / Line 248: @@
 <nowiki>*</nowiki>''Citation of this Page'': “Monoclonal B-cell lymphocytosis”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Monoclonal_B-cell_lymphocytosis</nowiki>.
-[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases M]]
+[[Category:HAEM5]]

Bailey.Glen at 18:52, 10 February 2025

2025-02-10T18:52:23Z

Show changes